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Gardner DS, Welham SJ, Dunford LJ, McCulloch TA, Hodi Z,
Sleeman P, O’Sullivan SE, Devonald MA. Remote conditioning or
erythropoietin before surgery primes kidneys to clear ischemia-reper-
fusion-damaged cells: a renoprotective mechanism? Am J Physiol
Renal Physiol 306: F873–F884, 2014. First published February 12,
2014; doi:10.1152/ajprenal.00576.2013.—Acute kidney injury is
common, serious with no specific treatment. Ischemia-reperfusion is a
common cause of acute kidney injury (AKI). Clinical trials suggest
that preoperative erythropoietin (EPO) or remote ischemic precondi-
tioning may have a renoprotective effect. Using a porcine model of
warm ischemia-reperfusion-induced AKI (40-min bilateral cross-
clamping of renal arteries, 48-h reperfusion), we examined the reno-
protective efficacy of EPO (1,000 iu/kg iv.) or remote ischemic
preconditioning (3 cycles, 5-min inflation/deflation to 200 mmHg of a
hindlimb sphygmomanometer cuff). Ischemia-reperfusion induced
significant kidney injury at 24 and 48 h (2, 1 degree of freedom,10
for 6/7 histopathological features). At 2 h, a panel of biomarkers
including plasma creatinine, neutrophil gelatinase-associated lipoca-
lin, and IL-1, and urinary albumin:creatinine could be used to predict
histopathological injury. Ischemia-reperfusion increased cell prolifer-
ation and apoptosis in the renal cortex but, for pretreated groups, the
apoptotic cells were predominantly intratubular rather than interstitial.
At 48-h reperfusion, plasma IL-1 and the number of subcapsular
cells in G2-M arrest were reduced after preoperative EPO, but not
after remote ischemic preconditioning. These data suggest an intrare-
nal mechanism acting within cortical cells that may underpin a
renoprotective function for preoperative EPO and, to a limited extent,
remote ischemic preconditioning. Despite equivocal longer-term out-
comes in clinical studies investigating EPO as a renoprotective agent
in AKI, optimal clinical dosing and administration have not been
established. Our data suggest further clinical studies on the potential
renoprotective effect of EPO and remote ischemic preconditioning are
justified.
potentially preventable; AKI; kidney; RIPC; EPO; cell cycle
ACUTE KIDNEY INJURY (AKI) imposes a heavy burden on patients
and on health services, being a common cause of in-hospital
morbidity and mortality. Warm ischemia with reperfusion
frequently results in AKI (2, 22). Despite being a potentially
preventable condition, the incidence of AKI has remained
unchanged for decades. A clearer understanding of the patho-
physiology of AKI, including association with serum or uri-
nary biomarkers at an early stage, is an important scientific and
clinical target (13) and enables targeted renoprotective inter-
ventions to be developed.
Human recombinant erythropoietin (EPO) is an established
drug for the treatment of renal anemia. EPO has been demon-
strated to be renoprotective in rodent models of ischemic (23,
27)-, sepsis (8)-, nephrotoxin (19)- or cold ischemia-reperfu-
sion-induced (5) AKI. A pilot clinical study reported encour-
aging preliminary results (26). However, substantial clinical
evidence for renoprotection by EPO is lacking (7, 9). In
contrast, remote ischemic preconditioning (RIPC), in which
short-term (1–5 min), nonlethal episodes (3–5 cycles) of limb
ischemia remote to the organ of interest result in attenuated
tissue injury during subsequent longer-term ischemia and rep-
erfusion, has been reported to offer considerable protection
against ischemia-reperfusion (IR)-induced organ damage.
RIPC has been demonstrated in the heart (4, 11), brain (12),
liver (1), and kidney (30), but negative results have also been
reported (17). A randomized-controlled clinical trial to ascer-
tain the effectiveness of RIPC for prevention of AKI is ongoing
(10). In common with EPO, the effectiveness and potential
mechanism of renoprotective action of RIPC have not been
described in detail in a relevant, preclinical large-animal
model.
In this study, we have first developed and optimized a
porcine model of AKI. The pig has a number of advantages
over other laboratory models that make it appropriate as a
preclinical animal model for the study of renal disease. First,
serial organ biopsies may be taken, allowing the time course of
injury to be determined. Second, such serial within-animal
sampling ensures less biological variation and thus fewer
animals may be used to achieve satisfactory statistical power.
Third, porcine kidneys are functionally and histologically sim-
ilar to human kidneys, likely responding to ischemia-reperfu-
sion-induced injury (IRI) in a similar fashion (16). Using our
porcine model of AKI, we tested the renoprotective efficacy of
preoperatively administered EPO or remote ischemic condi-
tioning. Our primary outcome was histopathological assess-
ment of the kidney at 24 h (by percutaneous biopsy) and at 48
h (after post mortem). Using an animal model allowed us to
relate time-resolved histopathology to a secondary outcome, a
serial analysis of potential AKI biomarkers in plasma [neutro-
phil gelatinase-associated lipocalin (NGAL), creatinine, urea,
albumin, osmolality, IL-1] and urine (creatinine, urea, albu-
min, osmolality, electrolytes) (2). From the biobanked tissue
samples after biopsy at 24 h or post mortem at 48 h, we
investigated the renal cortical cell response to injury using
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immunohistofluorescence for markers of the cell cycle and
apoptosis. Our data indicate that histopathological and physi-
ological changes in early AKI do not appear to correlate well.
However, a panel of early biomarkers provides evidence of
developing AKI. Our data suggest that plasma creatinine,
NGAL, and IL-1 together with the urinary albumin-to-creat-
inine ratio (ACR) at 2 h provide early noninvasive evidence of
developing AKI. We further show that the putative renopro-
tective value of EPO or RIPC pretreatment may relate to their
influence on renal cortical cell handling of apoptotic cellular
debris. Furthermore, in the short term, EPO but not RIPC
elicited a significant reduction in plasma IL-1 and reduced the
number of p-H3ve G2-M-arrested cells in the outer cortex
after IRI. This might be a mechanism by which EPO confers
renoprotection in AKI.
METHODS
Animals. All procedures were performed in accordance with the
UK Animals (Scientific Procedures) Act, (1986) and were approved
by the local ethical review committee of the University of Notting-
ham. Thirty female pigs [58  4.6 kg (means  SD)] were anesthe-
tized for general surgery [buprenorphine (0.05 mg/kg), ketamine (5
mg/kg), and detomidine (0.1 mg/kg)] with alfaxalone (0.7–2.4 mg/kg
iv), dosed to effect for intubation. Anesthesia was maintained with
isoflurane (1–2% in O2) and ventilated using a tidal volume of 10–12
ml/kg. A venous catheter was inserted for supportive fluid delivery
and vascular access. The depth of anesthesia and other parameters
were monitored during surgery and were not different across treat-
ment groups. A midline laparotomy was performed, and both the right
and left kidneys were revealed for renal artery cross-clamping (40
min), after which clamps were removed and the incision site closed.
A bladder catheter (12 Fr) was inserted for urine collection, and the
pigs were recovered to a pen. One sham control pig developed
malignant hyperthermia during anesthesia, was humanely euthanized
without recovery, and was excluded from analysis. Postoperative
analgesia was maintained with buprenorphine every 8 h for the first 24
h and thereafter every 12–24 h, including tramadol (4 mg/kg im) as
required.
Experimental design. Pigs were randomly assigned (sealed enve-
lope) to either a sham control (n  12, n  4/group) or IR (n  18,
n  6/group) group and to one of three treatment protocols: 1)
intravenous (iv) pretreatment with 5 ml saline; 2) iv pretreatment with
EPO at 1,000 iu/kg; or 3) pretreatment with RIPC, consisting of three
cycles of 5-min inflation to 200 mmHg, followed by 5-min deflation
of a sphygmomanometer cuff placed around a hind leg. Pretreatment
was conducted 30 min before induction of renal IRI. Plasma and urine
were sampled at intervals throughout the study and biobanked at
20°C for further analysis. A percutaneous right kidney biopsy was
performed with ultrasound guidance at 24 h, and pigs were lightly
sedated. An outline of the experimental design is given in Fig. 1.
Histopathology and immunohistofluorescence. At 48 h, all pigs
were humanely euthanized by a lethal dose of barbiturate (200
mg/kg), and selected tissues were snap-frozen in LN2 or fixed in 4%
paraformaldehyde and subsequently preserved. Histopathology and
immunohistofluorescence were conducted on 5-	m sections using
standard laboratory protocols. Each section from all animals was
assessed independently by two renal consultant histopathologists
blinded to the sample ID. Antibodies against PCNA (ab29) and
p-H3ser10 (ab5176) were purchased from Abcam (Cambridge, UK).
Sequence specificity for the protein of interest was 95% in each
case. Primary antibodies were used after heat-mediated antigen re-
trieval at a concentration of 1:1,000, with blocking by 10% neutral
goat serum. Secondary antibodies were either Alexa Fluor 544 used at
1:300 or Texas Red Goat anti-mouse (Invitrogen) used at 1:100. To
assess immune cell infiltration into kidney tissue, we used frozen
sections (10 	m) to quantify staining with swine leucocyte antigen
(SLA), which marks cells expressing the MHC class II (DR region;
MCA2314, Serotec) at the cell surface, and in paraffin-embedded
sections we used the anti-macrophage antibody MAC387 (ab22506,
Abcam).
Blood and urine chemistry. Plasma and urine albumin (g/l), creat-
inine (	mol/l), and urea (mmol/l) were measured by autoanalyzer
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Fig. 1. Outline of study design. Pigs were randomly assigned (sealed envelope) to either a sham control (n  12, n  4/group) or ischemia-reperfusion (IR; n 
18, n  6/group) group and to 1 of 3 treatment protocols: 1) intravenous (iv) pretreatment with 5 ml saline; 2) iv pretreatment with erythropoietin (EPO) at 1,000
iu/kg; or 3) pretreatment with remote ischemic preconditioning (RIPC), consisting of 3
 cycles of 5-min inflation to 200 mmHg, followed by 5-min deflation
of a sphygmomanometer cuff placed around a hind leg. Pretreatment was conducted 30 min before induction of renal IR injury. Plasma was obtained from serial
blood samples (10 ml into K-EDTA and heparinized tubes) taken from all animals before IR (30 min, baseline), post-RIPC (5 min), and postoperatively
at 2, 4, 6, 8, 24, and 48 h. Urine was spot-sampled at baseline and postoperatively at 2, 4, 6, 8, 24, and 48 h. Each was biobanked at 20°C for further analysis.
A percutaneous right kidney biopsy was performed with ultrasound guidance at 24 h, and pigs were lightly sedated. PM, post mortem.
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(RX-Imola, Randox, Co. Antrim, Northern Ireland, UK) with typical
interassay variation of 5%. Osmolality was measured by freezing
point depression (Osmomat 030, Gonotech). Electrolytes (Na and
Cl) were determined by inductively coupled mass spectrometry
(ICP-MS; XSeries II, Thermo Fisher) with intra-assay variability
being 2%. Plasma NGAL was measured using a commercially
available porcine-specific ELISA (Kit-044; Bioporte) following the
kit instructions; intra- and interassay variation was 5%. An array of
cytokines in plasma and kidney tissue lysates (IL-1, -1, -2, -4, -6,
-10, -12, -18 and TNF-) were measured using a porcine-specific
Illuminex assay, in magnetic bead format (PCYTMAG-23K, Milli-
pore).
Statistical analysis. Continuous data (e.g., plasma/urinary metabo-
lites) were analyzed using analysis of variance with IR (yes/no) 

treatment (saline/EPO/RIPC) plus interactions as fixed effects and
time (0–48 h) as a within-animal repeated measure, where appro-
priate. Nonparametric data were log10 transformed before analysis.
Ordinal data (e.g., ATN injury score) were analyzed by regression,
fitting Poisson (for categorical data) or binomial (yes/no) errors.
Significance was accepted with 2 (degrees of freedom, 1) 3.84. To
explore any relationship between fixed effects and AKI categories,
logistical generalized estimating equations were used, adjusted for
potential covariates (e.g. baseline plasma creatinine). P  0.050 was
accepted as indicating statistical significance. In addition, a multivar-
iate linear discriminant analysis that captured 95% variation from
all histopathological scores within treatment groups was used. The
number of pigs allocated per group was based on a previous pilot
study (n  5 pigs) in which histopathological score variability
between sham controls was minimal but was increased by IR. Hence,
we randomized by sealed envelope n  4/group for controls and n 
6/group for IR. Considering a 10% probability of detecting mild-
moderate acute kidney injury in the sham control group but a 90%
probability in the untreated IR group gives the study a power of 90%
with significance () set at 0.05.
RESULTS
Histopathology of the kidney after IRI. Forty-minute isch-
emia in the pig was determined as the optimal duration for
occlusion of the renal arteries to induce mild-moderate renal
injury, as opposed to severe injury that fails to recapitulate the
clinical picture (20). At 24 and 48 h after ischemia (by biopsy
and post mortem, respectively), the kidneys had significant
histopathological damage, which was not prevented by the
putative renoprotective treatments (Figs. 2 and 3).
Blood and urine chemistry after IRI. We performed longi-
tudinal analysis of metabolites and potential biomarkers in
plasma and urine before and after renal IR. At baseline, plasma
osmolality was 310 (307–313) mosmol/kgH2O-mean [95%
confidence interval (CI)] and remained unchanged regardless
of IR or treatment. In contrast, plasma creatinine, urea (P 
0.001, both cases), and NGAL (P  0.056) increased with IR
(Fig. 4, A–C). EPO and RIPC treatment appeared to blunt the
increase in NGAL with IR at 2 h, but not thereafter (Fig. 4B,
b1–b3). The change in urine biochemistry after IRI marked a
significant decline in kidney function with reduced urinary loss
of creatinine, urea, sodium, and reduced osmolality (Fig. 5).
However, ACR significantly increased, peaking as early as 2 h
post-IRI (Fig. 5C).
Cell survival or cell death after IRI. At 24 h after IRI, there
was a nonsignificant trend toward a greater number of terminal
deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end
labeling (TUNEL) TUNEL cells in the IR group [control, 0.2
(0.0–1.6) vs. IR, 1.2 (0.5–6.2); P  0.07 median interquartile
range (IQR)] that increased and became significant by 48 h
[control, 0.3 (0.0–2.0) vs. IR, 40 (0.0–84.5); P  0.01 median
IQR]. Notably, at 24 (Fig. 6) and 48 h (Fig. 7), both EPO- and
RIPC-pretreated IR groups exhibited a much greater proportion
of apoptotic (TUNEL) cells that were intratubular, colocal-
ized with proteinaceous casts in the distal tubules, rather than
randomly distributed throughout the cortex and outer medulla.
This suggested that pretreatment with EPO and RIPC in the
context of IRI may support an enhanced residual capacity of
the kidney to shed apoptotic cellular debris and facilitate
recovering tubular cells to proceed through the cell cycle,
rather than become arrested at the second checkpoint before
mitosis (G2-M) and become fibrotic, as has been shown in
mice (28). Hence we used immunofluorescence to identify
proliferative (PCNA, captures cells in late G1 and S-phase
during DNA synthesis) vs. nonproliferative (phospho-histone
3 p-H3, captures cells stalled in the G2-M phase) cells. IR
elicited a significant increase in PCNAve (Fig. 8A) and
p-H3ve cells (Fig. 8B). The area of PCNAve cells was
similar between IR groups (Fig. 8C). While the number of
p-H3ve cells increased from the subcapsular to corticomed-
ullary region (sequential field-of-view measurements from
subcapsular to corticomedullary junction; Fig. 8D), we also
found that the number of p-H3ve cells was significantly
less in the outer, but not inner, cortex of EPO-treated IR
animals (Fpr  0.021 for interaction; Fig. 8, E and F).
Furthermore, while IR was marked by an early increase in
plasma IL-1 that peaked at 8-h reperfusion (no other
cytokines were observed to increase significantly), in those
animals that had received preoperative EPO, but not saline
or RIPC, plasma IL-1 had returned to baseline and was
indistinguishable from sham controls by 24-h reperfusion
(Fig. 9). Accordingly, the concentration of kidney tissue
cytokines was not different in IR kidneys relative to sham
controls at 48-h reperfusion (Table 1), and immune cell
infiltration as marked by SLA (MHC-II) and macrophage
(MAC387) staining was unremarkable and not different
between groups at this time (data not shown).
DISCUSSION
Clinical context of AKI and renoprotective modalities. AKI
is a huge clinical problem worldwide. In the United Kingdom,
the Kidney Alliance has estimated that death rates from AKI
exceed those from methicillin-resistant Staphylococcus aureus
by 100-fold (AKI; between 62,000 and 210,000 vs MRSA; 364
in 2011; information at http://www.worldkidneyday.co.uk/)
costing the NHS up to £789 million per year. AKI, unlike many
other noncommunicable diseases, is preventable in many cases.
It has been estimated that, through the delivery of optimal
care, at least 12,000 lives and £130 –£186 million could be
saved. Nevertheless, over the last few decades treatment of
AKI has been at best supportive. Hence investigation of
potentially renoprotective therapies continues to receive
much attention. To date, preoperative administration of EPO
and RIPC are two putative renoprotective interventions that
have been studied in animal models and clinical trials. In
early rodent (8, 19, 23, 27), porcine (25) and clinical (26)
studies, preoperative EPO administration showed promise for
reducing aspects of AKI, but further clinical studies have subse-
quently proved disappointing (7, 9). In contrast, a number of
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clinical studies have shown that, after RIPC before surgery, acute
injury to organs (either heart, liver, brain, or kidney) was signif-
icantly reduced (3, 12, 14, 30), but negative results have also been
reported (17, 29). With this background of contrasting laboratory
and clinical studies, we developed the current large-animal pre-
clinical model of moderate AKI and tested the effectiveness of
EPO or RIPC pretreatment using a factorial design. With regard to
both of these interventions, and the AKI field in general, the
dataset is overwhelmingly derived from rodent models. Trans-
lation to clinical medicine has proved disappointing (20), a
phenomenon also observed in the field of inflammatory re-
search (21). In contrast, the pig is an excellent animal model
for renal research. It has similar relative organ mass, kidney
anatomy and physiology, and is large enough to allow serial
sampling of biofluids and organs. Acquisition of these data is
not ethically possible in humans and practically very difficult
in rodents. This is important, as organ biopsy remains the gold
standard for diagnosis of renal injury, and our study in the pig
allows for an interpretation of plasma and urinary biomarkers
in the context of time-resolved histopathology.
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Fig. 2. Histological assessment of acute kidney
injury in renal biopsies at 24 h indicates presence
of significant injury. Top: 2 pathologists, indepen-
dently and blinded to the provenance of sections,
scored on a discrete scale (0, no injury; 1, 1–10%;
2, 11–50%, 3, 50%) 4 histopathological param-
eters: epithelial flattening, necrotic casts, cell
sloughing, and interstitial infiltrate. Data are pre-
dicted mean scores [pooled estimated error for
main effects (sham vs. IR) represented by e.s.e.]
after ordinal regression analysis and adjustment for
pathologist (there was no significant difference
between pathologist for all scores). There was a
significant main effect of IR on epithelial flattening
{[2  9.88 (1 degree of freedom; df)], P 
0.007}, necrotic casts [2 44.6 (1 df), P 
0.001], and cell sloughing [2 14.7 (1 df), P 
0.002]. The number of glomeruli in biopsies was
sham, 12  2; IR, 8  2 (means  SE). Bottom:
representative photomicrographs of 5-	m paraffin-
embedded sections of biopsies from each treatment
group, stained with hematoxylin and eosin. Arrows
indicate damaged tubules.
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Fig. 3. Forty-minute ischemia with 48-h reperfusion induce significant renal histopathological injury. A: 2 pathologists, independently and blinded to the
provenance of sections, scored on a discrete scale (0, no injury; 1, 1–10%; 2, 11–50%, 3, 50%) 4 histopathological parameters: epithelial flattening, necrotic
casts, cell sloughing, and interstitial infiltrate and on a binomial scale (no 0 or yes 1) a further 3 histopathological parameters: the presence of edema, nuclear
regenerative features, and/or polymorphic nuclei. Data are predicted mean scores [pooled SE for main effects (sham vs. IR) represented by e.s.e.] after ordinal
regression analysis and adjustment for pathologist (there was no significant difference between pathologist for all scores). There was a significant main effect
of IR on epithelial flattening [2 34.1 (1 df), P  0.001], necrotic casts [2 52.9 (1 df), P  0.001], cell sloughing [2 51.1 (1 df), P  0.001] but no effect
on interstitial infiltrate [2 0.8 (1 df), P  0.36]. B: there was no evidence of edema, nuclear regenerative features, and polymorphs in sham controls (0/11
sections assessed), but each was increased with IR. C: combining all the assessed ordinal parameters (epithelial flattening, necrotic casts, cell sloughing, and
interstitial infiltrate) into a multivariate discriminant analysis (accounting for 97% variation in score) indicated a significant effect of IR per se [2 38.2 (20 df),
P  0.008], as represented by the first dimension in the discriminant plot [means (95% C.I., i.e., confidence interval) represented by circles]. D and E: IR
significantly increased relative kidney mass (per kg body wt), largely due to increased renal water retention or edema, confirming the histopathological
assessment. Putative renoprotection by EPO or RIPC had no effect on histopathological injury. Data were analyzed as an IR (2 levels; yes/no) 
 treatment (3
levels; saline/EPO/RIPC) factorial ANOVA with interaction (controls, n  11: saline, n  4; EPO, n  3; RIPC, n  4 vs IR, n  17: IR-saline, n  6; IR-EPO,
n  6; IR-RIPC, n  5). Statistical significance was accepted at P  0.05. Where appropriate for each group, horizontal lines are means with vertical lines,
95% C.I.
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A porcine model of AKI: prevention of histopathological
damage by EPO or RIPC? We show that clamping both renal
arteries of the pig for 40 min elicited moderate to severe
histopathological injury by 24 h which lasted until at least 48-h
reperfusion. It has been reported that a similar duration (aver-
age time, 37 min) of warm IR in humans undergoing partial
nephrectomy for excision of a renal mass incurred little histo-
pathological injury (16). However, injury was assessed at
5-min reperfusion in that study. Our new data in the pig would
suggest that marked injury does develop after 40-min IR, and
significant tubular damage is evident at 24 h. The predominant
histopathological finding in our study was epithelial cell flat-
tening with cell sloughing in proximal tubules together with the
presence of necrotic casts in distal tubules. Edema and nuclear
dedifferentiation were also notable responses. Renal edema
was confirmed at post mortem by freeze drying kidney tissue.
In this short-term study, neither EPO nor RIPC prevented any
aspect of this intrarenal damage. While traditional biomarkers
such as plasma creatinine marked injury throughout the study,
alternative biomarkers such as ACR were resolving, being
similar to baseline at 24 h despite significant histopathological
injury at this time. This highlights the temporal discrepancies
between biomarkers and tissue diagnosis and provides further
evidence of the importance of using more than one biomarker
in clinical practice. Identification of an early decisive bio-
marker is important, and we show here for the first time that by
using a combination of established (urinary ACR and plasma
creatinine) and novel (plasma NGAL, IL-1) biomarkers, a
noninvasive prediction of AKI may be made as early as 2 h
after reperfusion in this model.
Cellular response in the renal cortex to IRI in pigs. Renal
IRI, at a cellular level, is characterized in vitro and in vivo
(laboratory mammals) by apoptosis, necrosis, and immune cell
infiltration (2, 22). This phenotype is virtually absent from
control animals in the current study but prevalent (apoptosis) in
the untreated (saline-infused) pig with AKI at 24 h, becoming
significantly worse by 48-h reperfusion (Fig. 4). The mecha-
nism of renoprotective action of EPO has been proposed to be
antiapoptotic (15, 24). While we do not observe a treatment
effect of EPO per se on the numbers of TUNELve cells, we do
observe a distinctive distribution of apoptotic cells with IRI
and after treatment with either EPO or RIPC, but not saline
(see Figs. 6 and 7). They were clearly shed, together with other
cell debris, into tubules and had coalesced in necrotic casts in
distal tubules, rather than being spread throughout the tubular
and interstitial cells of the renal cortex. This phenotype was
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Fig. 4. Increment in plasma creatinine, urea, and neutrophil gelatinase-associated lipocalin (NGAL) mark significant renal injury, but for the first 2 h after IR
plasma NGAL is blunted by EPO and RIPC. A–C: plasma was obtained from serial blood samples taken from all animals before IR (30 min, “base” and 5
min, “0”) and subsequently at 2, 4, 6, 8, 24, and 48 h. Data were first log10 transformed and analyzed as an IR (2 levels; yes/no) 
 treatment (3 levels;
saline/EPO/RIPC) 
 time (7 levels, analyzed as a repeated measure) factorial ANOVA with interaction (controls, n  11: saline, n  4; EPO, n  3; RIPC,
n  4 vs. IR, n  17: IR-saline, n  6; IR-EPO, n  6; IR-RIPC, n  5). Data are predicted mean logs  SE from the model, presented on an antilog scale
for clarity. B1–B3: boxplots are change () in plasma NGAL at 2, 4, or 8 h relative to baseline. Vertical shaded area represents the period of ischemia, and
horizontal shaded area represents the baseline range (95% C.I.) for plasma NGAL. Statistical significance was accepted at P  0.05. Boxes are IQR (line at
median), and whiskers are the 5–95% C.I. for group data.
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 time (7 levels, analyzed as a repeated measure) factorial ANOVA with interaction (controls, n  11: saline, n  4;
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the main effect of sham vs. IR is presented.
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observed in post mortem tissue at 48 h but also, importantly, in
the renal biopsy at 24 h. This suggested to us that the mecha-
nism of renoprotection offered by EPO or RIPC may involve
the cell cycle. Rather than cells becoming stalled at the second
checkpoint (G2-M) and progressing to fibrosis (28), EPO and
RIPC were stimulating a prosurvival response that included a
greater capacity of renal tubular cells to shed apoptotic and
necrotic debris. Using immunofluorescence, we observed an
increased propensity toward cell dedifferentiation and prolif-
eration (marked by an increased number of PCNAve cells and
validating the histopathological assessment) together with an
increased number of cells stalled at G2-M after IRI in all
groups. This effect became progressively greater from the
subcapsular to corticomedullary region in the renal cortex.
However, a consideration of the regional distribution of
p-H3ve cells in the group pretreated with EPO indicated
successful rescue of cells from cell cycle stalling in the sub-
capsular (outer cortex) but not in deeper cortical regions (e.g.,
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Fig. 6. Pretreatment with EPO or RIPC pro-
motes shedding of terminal deoxynucleotidyl
transferase(TdT)-mediated dUTP nick-end
labeling (TUNEL)ve apoptotic cells into
tubules at 24-h post-IR. Data are representa-
tive microphotographs of renal biopsy tissue
(right kidney; n  3–5/group) sampled at
24-h reperfusion and taken from paraffin-
embedded sections. Fluorescently labeled
apoptotic nuclei (TUNEL cell-death detec-
tion kit, Roche) were visualized using an
FITC filter on a Nikon Eclipse 80i micro-
scope with a DS-Qi1Mc digital camera and
contrasted against propidium iodide (PI)
cells as a general nuclear marker. Immuno-
histofluorescent sections were visualized us-
ing EPO and RIPC.
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Fig. 7. Pretreatment with EPO or RIPC promotes shedding of TUNELve apoptotic cells into tubules at 48-h post-IR. Data are representative microphotographs
of single kidney sections (n  3–5/group) from paraffin-embedded tissue recovered at post mortem (48-h reperfusion). Fluorescently labeled apoptotic nuclei
(TUNEL cell-death detection kit, Roche) were visualized using an FITC filter on a Nikon Eclipse 80i microscope with a DS-Qi1Mc digital camera and contrasted
against propidium iodide (PI) cells as a general nuclear marker. Immunohistofluorescent sections were visualized using EPO and RIPC.
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corticomedullary junction). The IL-1 family of cytokines, in
particular, IL-1, TGF-, and IL-18, are proinflammatory
upon activation and have been suggested to contribute to, and
mark, renal IR-injury (2). Uromodulin/Tamm-Horsfall protein
is produced from the thick ascending limb of the loop of Henle
with renal damage that exposes the interstitium (as observed
here) and exacerbates renal IL-1 production (6). In our
large-animal model, we show for the first time that EPO, but
not RIPC, blunted the IR-induced increase in plasma IL-1. At
8-, 24-, and 48-h reperfusion, values for IL-1 in the IR-EPO
group were at or near control levels, in contrast to in the IR and
IR-RIPC groups which remained high. Thus pretreatment with
EPO, but not RIPC, appears to blunt some aspects of the early
sterile inflammatory response that characterizes acute kidney
injury and rescues outer cortical cells from becoming arrested
in the cell cycle. However, serial jugular blood sampling is
only able to show temporal changes to cytokines as reflected in
organ spillover into the general circulation. This is likely a
crude estimation of the postischemic, intraorgan inflammatory
response in which waves of inflammatory activity engender
different roles within the organ in a time-dependent fashion
(2). The current data, limited to renal tissue samples at 24 and
48 h, are unlikely to suitably capture this response. Indeed,
in our model at 48-h reperfusion, we observed no evidence
p-
H
3s
er
10
(n
um
b e
r+
v e
ce
lls
)
Control IR
0
10
20
30
40
IR, Fpr=0.002
A B
PC
N
A
(n
um
be
r+
ve
ce
lls
)
Control IR
0
100
200
300
400
500 IR, Fpr=0.01
PC
N
A
+v
e
ce
lls
(µ
m
2
pe
rF
O
V)
- - - + + +
0
200
400
600
800
EPO - -+ - -+
IR
RIPC - +- - +-
IR, Fpr=0.006
C
p-
H
3s
er
10
(n
um
be
r+
ve
ce
lls
)
- - - + + +
0
10
20
30
EPO - -+ - -+
IR
RIPC - +- - +-
Subcapsular
IR × treatment × location, Fpr=0.02
E F
- - - + + +
0
10
20
30
EPO - -+ - -+
IR
RIPC - +- - +-
Cortico-medullary junction
D
p-
H
3s
er
10
(n
um
be
r+
ve
ce
lls
)
su
b-c
ap
su
lar
ou
ter
co
rte
x
inn
er
co
rte
x
co
rti
co
-m
ed
ull
ary
su
b-c
ap
su
lar
ou
ter
co
rte
x
inn
er
co
rte
x
co
rti
co
-m
ed
ull
ary
0
2
4
6
8
IR - - + +- - + +
Location
Location, Fpr=<.001
IR × location, Fpr=0.04
G
Fig. 8. Renal IRI increases the number of
PCNAve and p-H3ve cells, indicating an
increase in proliferative activity at G1-S and
G2-M, respectively, but EPO reduces the
number of subcapsular cells in G2-M arrest.
Data are from immunofluorescent analysis of
single kidney sections per animal (n  3–5/
group) from paraffin-embedded tissue recov-
ered at post mortem (48-h reperfusion). Sec-
tions were prepared for immunofluorescence
by heat-mediated antigen retrieval and label-
ing with a porcine-specific primary antibody
to proliferating cell nuclear antigen (PCNA)
for proliferative cells and to phospho-histone
3 (p-H3ser10) for nonproliferative cells stalled
in G2-M. Sections were counterstained with
DAPI. Specificity of the antibodies was con-
firmed by using appropriate negative controls
(omitting the primary and using an IgG iso-
type). Positive cells were visualized using an
FITC filter on a Nikon Eclipse 80i micro-
scope with a DS-Qi1Mc digital camera. Data
were first log10 transformed and analyzed as
IR (2 levels; yes/no) 
 treatment (3 levels;
saline/EPO/RIPC) 
 location (5 levels rep-
resenting separate fields-of-view from the
subcapsular area to inner corticomedullary
junction). Quantitative data (controls, n 
11: saline, n  4; EPO, n  3; RIPC, n  4
vs. IR, n  18: IR-saline, n  6; IR-EPO,
n  6; IR-RIPC, n  5) were analyzed using
a generalized linear mixed model with the
individual included as a random effect and
errors fitted with a Poisson distribution. Data
are observed counts of positive nuclei (A,
C–F) or predicted means  SE. from the
model (B). In pigs with IR-induced kidney
injury, the numbers of proliferative cells
were increased (A and B) as were the num-
bers of cells stalled in G2-M (C and D);
however, EPO pretreatment reduced the
number of G2-M cells in the outer cortex.
G: representative microphotograph of PCNAve
staining. Statistical significance was accepted
at P  0.05.
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for greater immune cell infiltration after IRI (analysis of
kidney lysate cytokines, quantification of cells expressing
MHC-II, abundance of tissue macrophages). Nevertheless,
blunting of IL-1 by EPO after IR is of interest and may
mitigate progression of AKI to chronic kidney disease in
this group (2, 28).
In summary, we asked whether EPO or RIPC delivered
preoperatively could protect against AKI. Clinical studies have
shown efficacy for each intervention, to some extent, but the
data are ambiguous and the mechanisms remain elusive. We
optimized and characterized a preclinical animal model allow-
ing us to investigate potential mechanisms through serial sam-
pling of biofluids and renal histology, together with character-
ization of renal tissue responses. First, using this model, we
identify the dissociation between renal physiology, as assessed
through serial sampling of biofluids, and histopathology. For
example, moderate to severe kidney injury was histologically
evident at 24-h reperfusion despite resolving blood and urine
chemistry. This could be an important consideration for the
clinician interpreting noninvasive biomarkers. Our data sug-
gest that a 2-h measurement of plasma creatinine, NGAL,
IL-1, and urinary ACR would provide the earliest biomarker
panel for predicting AKI. Furthermore, we have demonstrated
EPO- and, to a lesser extent, RIPC-associated cellular effects,
which could be potentially renoprotective. These data suggest
that there is merit in investigating the putative renoprotective
effect of EPO, and possibly RIPC, further. Despite equivocal
outcomes in clinical studies investigating EPO as a renopro-
tective agent in AKI, optimal clinical dosing and administra-
tion of EPO have not been established and our data suggest that
further clinical studies are justified.
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Table 1. Kidney tissue cytokines in pigs exposed to control (sham surgery) or ischemia-reperfusion (IR) with 48-h reperfusion
Treatment P Value
Cytokine, pg·ml1·mg protein1 Group saline EPO RIPC SED G Tr G 
 Tr
IFN- Sham 0.41 2.55 2.56 2.04 0.13 0.54 0.45
IR 2.16 0.45 2.66
IL-1 Sham 0.012 0.012 0.011 0.002 0.83 0.93 0.93
IR 0.012 0.012 0.012
IL-1 Sham 0.063 0.062 0.054 0.036 0.20 0.75 0.79
IR 0.067 0.095 0.100
IL-2 Sham 0.221 0.259 0.192 0.066 0.40 0.57 0.28
IR 0.227 0.132 0.204
IL-4 Sham 0.412 0.461 0.366 0.150 0.74 0.59 0.46
IR 0.461 0.267 0.409
IL-6 Sham 0.004 0.007 0.005 0.003 0.18 0.67 0.83
IR 0.007 0.008 0.009
IL-8 Sham 0.069 0.075 0.057 0.016 0.44 0.99 0.37
IR 0.055 0.053 0.066
IL-10 Sham 0.022 0.026 0.023 0.006 0.30 0.67 0.46
IR 0.023 0.015 0.021
IL-12 Sham 0.014 0.015 0.014 0.003 0.40 0.63 0.49
IR 0.013 0.010 0.015
IL-18 Sham 0.816 0.830 0.876 0.226 0.64 0.28 0.54
IR 0.972 0.692 1.077
TNF- Sham 0.002 0.003 0.003 0.001 0.81 0.54 0.54
IR 0.003 0.001 0.003
Cytokines were analyzed (pg/ml) in kidney tissue lysates (RIPA buffer) by Luminex array (Millipore). Data are predicted means with standard error of the
differences between means (SED.) used to represent the residual error. There were n  3–6 pigs/treatment group (29 pigs in total) analyzed in a 2 (sham, IR 

3 (saline, erythropoietin; EPO, remote ischemic preconditioning; RIPC) factorial design by ANOVA (Genstat v14). G, group; Tr, treatment; df, degrees of
freedom. Protein (mg/ml) was determined in lysates by the Bradford method. Statistical significance was accepted at P  0.05, with 95% confidence interval
(CI) as 2.07 (df6,23) 
 SED.
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